Global Oxytocin market are set to experience a significant growth of 9.0% CAGR from 2022 to 2030, with an estimated market value of around US$ 83.0 Mn as of 2022. As per Future Market Insights’ projections, Postpartum type holds a substantial share of over 88.8% in 2021 within the Global market.
| Data Points | Market Insights |
|---|---|
| Market Value 2021 | US$ 76.0 Million |
| Market Value 2022 | US$ 83.0 Million |
| Market Value 2030 | US$ 164.9 Million |
| CAGR 2022-2030 | 9.0% |
| Market Share of Top 5 Countries | 51.2% |
| Key Market Players | Pfizer Inc., Novartis AG, Ferring B.V., Fresenius Kabi LLC, Hikma Pharmaceuticals PLC, Endo International plc. (Par Sterile Products, LLC), Teva Pharmaceutical Industries Ltd., Mylan N.V., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 8.41% |
| H1, 2022 Projected | 8.96% |
| H1, 2022 Outlook | 8.96% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (+) 45 ↑ |
As compared to H1-2021, the oxytocin market is expected to surge by 45 basis point share (BPS) in H1-2022 (O), according to FMI. However, comparison analysis for the H1-2022 projected and H1-2022 outlook period reflected a decline in growth rate by nearly 10 BPS.
The use of high-quality injectable oxytocin to effectively prevent and treat postpartum haemorrhage, the main cause of maternal death worldwide, is one of the key reasons contributing to the rise in BPS.
FMI provides a comparative study of the global oxytocin market's growth rates and development prospects. Market authorization and regulatory approvals, as well as the impact of macro and industrial factors, have an impact on the market. The introduction of FDA-approved exogenous oxytocin in the antepartum phase for enhancing uterine contractions with the goal of a successful vaginal birth of the foetus is a key development in this sector.
The thermal sensitivity of oxytocin, which can result in its quality being deteriorated at several points along the health supply chain, including at the manufacturing site owing to low quality of API, a dearth of sterile production systems, or poor production methods, and during storage and transport caused by a lack of temperature regulation in the distribution network, including co-packaging, can conversely provide a restrictive growth impact on the oxytocin market.
The Oxytocin market holds nearly 6.3% of the overall US$ 1.2 Bn Growth Hormones market in 2021.
The market of oxytocin on a global scale is considered extremely fragmented, with numerous local and multinational players active. Most products purchased from local players are provided by the National Government Procurement Agencies to the local governments. Thus, several developing countries are dependent upon local players, leading to an increase in focus on procurement of high volumes for lower costs.
The global oxytocin market includes an increase in the licensing activities of companies to develop new therapeutics for a range of indications.
The global oxytocin industry is set to be driven by factors including the rapidly growing global birth rate as well as the raised complications associated with birth. The overuse of caesarean delivery is expected to grow in the future which can create an unmet need of oxytocin treatment in the market. The pregnancy awareness programs offered by the local governments, NGOs and regulatory bodies are further expected to increase the awareness about the pregnancy care and healthcare setup based birth in the developing regions. The increasing awareness about pregnancy and the complications associated with it are thus the factors likely to ascend the boost in sales of oxytocin based products, thus increasing the market share growth of the oxytocin industry.
Rising demand for healthcare setup based pregnancy births and developments of high quality oxytocin therapeutics are re-shaping the therapeutic landscape in haemorrhage treatment in pregnancy. The current trend of “postpartum haemorrhage prevention” strategy is more suitable for reasons of medical need, efficacy, or desirability—has emerged as an accepted and valuable alternative to haemorrhage treatment, thus swiftly affecting the rise in oxytocin industry value.
Moreover, leading healthcare organizations at national, regional and global level are recommending the use of oxytocin as prophylactic first-line treatment for the prevention and treatment of pregnancy and birth associated haemorrhage cases globally.
The market is expected to expand at a considerable growth rate over the next eight years at a CAGR of close to 9.0%, and offer an absolute $ opportunity of US$ 7.7 Mn from 2021-2022. The above mentioned factors compile the sales outlook of the global oxytocin market, and are expected to raise value in the overall healthcare industry.
Increasing healthcare expenditure and per capita income offers unique opportunity for leading oxytocin manufacturers to expand their presence in the emerging market such as Africa, China and India market.
Emerging scientific and technological advancements offers potential opportunities to expand the oxytocin indication to emerging applications such as pregnancy complication, autism, social anxiety and many others. These new indications are in development phases or being preferred to use off-label but in future they could offer potential growth opportunities.
Oxytocin therapeutic with incremental innovation such as high stability of formulation, development of new convenient dosage forms, high efficacy and potency versions are expected to provide potential opportunities for the leading companies in the global oxytocin market.
Most of the market opportunities in the global oxytocin market are present in developing region with complex nature of the market. In addition, the market is highly competitive and majorly operates by local players. Hence, the collaborative approach and partnership will offer high market penetration and growth opportunities.
Principal Consultant
The availability of alternate drugs like misoprostol and magnesium sulphate for labour induction or PPH treatment could hamper the growth of oxytocin market. Moreover, misoprostol available in tablet form unlike oxytocin which is in injection form, making product more stable and easily accessible for resource-poor countries.
Manufacturers in many countries are not obtaining WHO prequalification for manufacturing of oxytocin products. This leads to production of substandard quality of drugs in the market, thus, hampering its growth.
The current market structure where large number of manufacturers are creating high price-sensitive market. That makes this market less adherent to the required regulation owing to the cost involved in the upgradation of the manufacturing facilities.
Oxytocin has been used in the dairy farming sector to enhance lactation, to speed up the ripening of fruits and vegetables. The misuse of the drug can cause deterioration of milch cattle.
The increasing complaints and misuse of the oxytocin drugs resulted in a Government implied ban on all private sector companies for manufacturing and distributing oxytocin for domestic use in India without registration and cGMP practices.
The U.S. dominates the North American region with a total market share of about 91.5% in 2021, and is projected to continue experiencing high growth throughout the forecast period. The growth of this market is driven by increasing awareness regarding pregnancy products and increasing expenditure on personal care products within the country. The rising responsiveness has resulted in successful pregnancy-related awareness programs and maternal and child health has inducted itself as an essential element of the U.S. healthcare system.
Germany is set to exhibit a CAGR of about 6.6% in the European Oxytocin market during the forecast period. The country has essentially incorporated advanced maternity care, resulting in proliferation of sales in the European region for oxytocin products. Presence of large industry players with key research impact upon the overall market structure, such as Novartis, in the region is further expected to present Germany as a lucrative research, development and production hub for oxytocin products in the European region throughout the forecast period.
China holds 67.3% share in the East Asia market in 2021, and is projected to increase at a CAGR rate of 6.2% during the forecast period. The growth of the Oxytocin market in the country is attributed to the rising wave of automation and robotic assistive devices in the region of East Asia, with China as the prime contributor in the development industry for robotic devices for various intended uses, including Oxytocin for orthopaedic procedures. As a global manufacturing hub, China is likely to pose an increasing demand trend over the forecast period.
In 2021, Japan held a 26.0% share in the East Asia Oxytocin market, and is projected to expand at a CAGR of 6.9% from 2022 to 2030. The rising research interest in Japan for novel therapeutics and hormonal therapy have promoted the region of East Asia as upcoming in terms of generating spurred revenues globally.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Postpartum product types project a lucrative growth at a CAGR of 8.7% till the end of the forecast period, with a market share of over 88.8% in 2021. The applications and use of postpartum oxytocin products has resulted in the decrease of post-partum haemorrhage, and thus is being gradually adopted over the globe with a collective gain of lowered maternal mortality.
Hospital Pharmacies hold a revenue share of 63.8% in 2021 and are projected to hold a share over the forecast period with the estimation being 87.0%. A majority of procedures involving the use of Oxytocin are performed within the hospitals. Moreover, hospital networks promote the purchasing power for Oxytocin market and are thus dominant as a Distribution Channel segment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The leading global oxytocin market players are focusing on research and development of innovative products with competitive advantages. The oxytocin market is a highly fragmented with a large number of local and multinational players operating in the market worldwide. The majority of the products in oxytocin market are procured from the local players by the national procurement agencies of the local governments.
Similarly, recent developments related to companies manufacturing Oxytocin products have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2030 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, China, Japan, South Korea, India, Malaysia, Indonesia, Thailand, Australia,New Zealand, GCC Countries, Turkey, Egypt, Nigeria, Algeria, Morocco, Kenya |
| Key Market Segments Covered | Product Distribution Channel and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global Oxytocin market is worth US$ 76.0 Mn at present, and is set to expand 2X over the next eight years.
The Oxytocin market is expected to reach US$ 164.9 Mn by the end of 2030, with sales revenue expected to register 9.0% CAGR.
Highly fragmented market, increased licensing activities and WHO prequalification are some of the key trends being witnessed in this marketplace.
The China, U. S., India, Canada and Japan are expected to drive demand for Oxytocin products.
North America is one of the key markets for Oxytocin, with the U.S. expected to account over 90.8% of the North American market revenue share during the forecast period.
Demand for Oxytocin in Europe is expected to register growth of 9.2% over the next seven years.
The U.S., India and Canada are key producers of Oxytocin products.
Pfizer Inc., Novartis AG, Ferring B.V., Fresenius Kabi LLC, Hikma Pharmaceuticals PLC, Endo International plc. (Par Sterile Products, LLC), Teva Pharmaceutical Industries Ltd., Mylan N.V., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation are the key exporters of Oxytocin market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Strategic Promotional Strategies
4.3. Regulatory Scenario
4.4. Disease Epidemiology
5. Global Oxytocin Market - Pricing Analysis
5.1. Regional Pricing Analysis By Indication
5.2. Pricing Break-up
5.2.1. Manufacturer Level Pricing
5.2.2. Distributor Level Pricing
5.3. Global Average Pricing Analysis Benchmark
6. Global Oxytocin Market Demand (in Volume) Analysis 2015-2021 and Forecast, 2022-2030
6.1. Historical Market Volume (Units Mn) Analysis, 2015-2021
6.2. Current and Future Market Volume (Units Mn) Projections, 2022-2030
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Oxytocin Market Demand (in Value or Size in US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030
7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Healthcare Expenditure Outlook
8.2. Forecast Factors - Relevance & Impact
8.2.1. Increasing Prevalence of Pregnancy Complications
8.2.2. Rising number of Birth Globally
8.2.3. Growing Awareness of Induced Labour and Breastfeeding
8.3. Value Chain
8.4. Market Dynamics
8.4.1. Drivers
8.4.2. Restraints
8.4.3. Opportunity Analysis
9. COVID19 Crisis Analysis
9.1. Current COVID19 Statistics and Probable Future Impact
9.2. Current GDP Projection and Probable Impact
9.3. Current Economic Projection as compared to 2008 financial analysis
9.4. COVID19 and Impact Analysis
9.4.1. Revenue By Product
9.4.2. Revenue By Country
9.5. 2020 Market Scenario
9.6. Quarter by Quarter Forecast
9.7. Projected recovery Quarter
9.8. Recovery Scenario – Short term, Midterm and Long Term Impact
10. Global Oxytocin Market Analysis 2015-2021 and Forecast 2022-2030, by Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2021
10.3. Current and Future Market Size (US$ Mn) and Forecast By Indication, 2022 - 2030
10.3.1. Antepartum
10.3.2. Postpartum
10.4. Market Attractiveness Analysis By Indication
11. Global Oxytocin Market Analysis 2015-2021 and Forecast 2022-2030, by Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2015 - 2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 - 2030
11.3.1. Hospital Pharmacies
11.3.2. Drug Stores
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Oxytocin Market Analysis 2015-2021 and Forecast 2022-2030, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis by Region, 2015 - 2021
12.3. Current Market Size (US$ Mn) Analysis and Forecast by Region, 2022 - 2030
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. Middle East and Africa (MEA)
12.3.5. East Asia
12.3.6. South Asia
12.3.7. Oceania
12.4. Market Attractiveness Analysis by Region
13. North America Oxytocin Market Analysis 2015-2021 and Forecast 2022-2030
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
13.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.2. By Indication
13.4.3. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Indication
13.5.3. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
14. Latin America Oxytocin Market 2015-2021 and Forecast 2022-2030
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
14.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Argentina
14.4.1.4. Rest of Latin America
14.4.2. By Indication
14.4.3. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Indication
14.5.3. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Europe Oxytocin Market 2015-2021 and Forecast 2022-2030
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
15.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. U.K.
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Rest of Europe
15.4.2. By Indication
15.4.3. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Indication
15.5.3. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. South Asia Oxytocin Market 2015-2021 and Forecast 2022-2030
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
16.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
16.4.1. By Country
16.4.1.1. India
16.4.1.2. Thailand
16.4.1.3. Indonesia
16.4.1.4. Malaysia
16.4.1.5. Rest of South Asia
16.4.2. By Indication
16.4.3. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Indication
16.5.3. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. East Asia Oxytocin Market 2015-2021 and Forecast 2022-2030
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
17.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
17.4.1. By Country
17.4.1.1. China
17.4.1.2. Japan
17.4.1.3. South Korea
17.4.2. By Indication
17.4.3. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Indication
17.5.3. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18. Oceania Oxytocin Market 2015-2021 and Forecast 2022-2030
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
18.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
18.4.1. By Country
18.4.1.1. Australia
18.4.1.2. New Zealand
18.4.2. By Indication
18.4.3. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Indication
18.5.3. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Middle East and Africa Oxytocin Market 2015-2021 and Forecast 2022-2030
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2021
19.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2022 - 2030
19.4.1. By Country
19.4.1.1. GCC Countries
19.4.1.2. South Africa
19.4.1.3. Egypt
19.4.1.4. Nigeria
19.4.1.5. Algeria
19.4.1.6. Morocco
19.4.1.7. Kenya
19.4.1.8. Rest of Middle East and Africa
19.4.2. By Indication
19.4.3. By Distribution Channel
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Indication
19.5.3. By Distribution Channel
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
20. Emerging & Key Countries Oxytocin Market Analysis
20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. U.S. Oxytocin Market Analysis
20.2.1. By Indication
20.2.2. By Distribution Channel
20.3. Canada Oxytocin Market Analysis
20.3.1. By Indication
20.3.2. By Distribution Channel
20.4. Mexico Oxytocin Market Analysis
20.4.1. By Indication
20.4.2. By Distribution Channel
20.5. Brazil Oxytocin Market Analysis
20.5.1. By Indication
20.5.2. By Distribution Channel
20.6. Argentina Oxytocin Market Analysis
20.6.1. By Indication
20.6.2. By Distribution Channel
20.7. Germany Oxytocin Market Analysis
20.7.1. By Indication
20.7.2. By Distribution Channel
20.8. Italy Oxytocin Market Analysis
20.8.1. By Indication
20.8.2. By Distribution Channel
20.9. France Oxytocin Market Analysis
20.9.1. By Indication
20.9.2. By Distribution Channel
20.10. U.K. Oxytocin Market Analysis
20.10.1. By Indication
20.10.2. By Distribution Channel
20.11. Spain Oxytocin Market Analysis
20.11.1. By Indication
20.11.2. By Distribution Channel
20.12. Russia Oxytocin Market Analysis
20.12.1. By Indication
20.12.2. By Distribution Channel
20.13. China Oxytocin Market Analysis
20.13.1. By Indication
20.13.2. By Distribution Channel
20.14. Japan Oxytocin Market Analysis
20.14.1. By Indication
20.14.2. By Distribution Channel
20.15. S. Korea Oxytocin Market Analysis
20.15.1. By Indication
20.15.2. By Distribution Channel
20.16. India Oxytocin Market Analysis
20.16.1. By Indication
20.16.2. By Distribution Channel
20.17. Malaysia Oxytocin Market Analysis
20.17.1. By Indication
20.17.2. By Distribution Channel
20.18. Thailand Oxytocin Market Analysis
20.18.1. By Indication
20.18.2. By Distribution Channel
20.19. Indonesia Oxytocin Market Analysis
20.19.1. By Indication
20.19.2. By Distribution Channel
20.20. Australia Oxytocin Market Analysis
20.20.1. By Indication
20.20.2. By Distribution Channel
20.21. New Zealand Oxytocin Market Analysis
20.21.1. By Indication
20.21.2. By Distribution Channel
20.22. GCC Countries Oxytocin Market Analysis
20.22.1. By Indication
20.22.2. By Distribution Channel
20.23. Turkey Oxytocin Market Analysis
20.23.1. By Indication
20.23.2. By Distribution Channel
20.24. South Africa Oxytocin Market Analysis
20.24.1. By Indication
20.24.2. By Distribution Channel
20.25. Egypt Oxytocin Market Analysis
20.25.1. By Indication
20.25.2. By Distribution Channel
20.26. Nigeria Oxytocin Market Analysis
20.26.1. By Indication
20.26.2. By Distribution Channel
20.27. Algeria Oxytocin Market Analysis
20.27.1. By Indication
20.27.2. By Distribution Channel
20.28. Morroco Oxytocin Market Analysis
20.28.1. By Indication
20.28.2. By Distribution Channel
20.29. Kenya Oxytocin Market Analysis
20.29.1. By Indication
20.29.2. By Distribution Channel
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Concentration
21.3. Market Share Analysis of Top Players
21.4. Market Presence Analysis
21.4.1. By Regional Footprint of Players
21.4.2. Product Footprint by Players
21.4.3. Channel Footprint by Players
22. Competition Analysis
22.1. Competition Dashboard
22.2. Pricing Analysis by Competition
22.3. Competition Benchmarking
22.4. Competition Deep Dive
22.5. Key Players Based On Estimated Tracked Revenue
22.5.1. Pfizer Inc.
22.5.1.1. Indication Portfolio
22.5.1.2. Profitability by Market Segments (Channel/Region)
22.5.1.3. Sales Footprint
22.5.1.4. Analyst commentary
22.5.1.5. Strategy Overview
22.5.1.5.1. Marketing Strategy
22.5.1.5.2. Product Strategy
22.5.1.5.3. Channel Strategy
22.5.2. Novartis AG
22.5.2.1. Indication Portfolio
22.5.2.2. Profitability by Market Segments (Channel/Region)
22.5.2.3. Sales Footprint
22.5.2.4. Analyst commentary
22.5.2.5. Strategy Overview
22.5.2.5.1. Marketing Strategy
22.5.2.5.2. Product Strategy
22.5.2.5.3. Channel Strategy
22.5.3. Ferring B.V.
22.5.3.1. Indication Portfolio
22.5.3.2. Profitability by Market Segments (Channel/Region)
22.5.3.3. Sales Footprint
22.5.3.4. Analyst commentary
22.5.3.5. Strategy Overview
22.5.3.5.1. Marketing Strategy
22.5.3.5.2. Product Strategy
22.5.3.5.3. Channel Strategy
22.5.4. Fresenius Kabi LLC
22.5.4.1. Indication Portfolio
22.5.4.2. Profitability by Market Segments (Channel/Region)
22.5.4.3. Sales Footprint
22.5.4.4. Analyst commentary
22.5.4.5. Strategy Overview
22.5.4.5.1. Marketing Strategy
22.5.4.5.2. Product Strategy
22.5.4.5.3. Channel Strategy
22.5.5. Hikma Pharmaceuticals PLC
22.5.5.1. Indication Portfolio
22.5.5.2. Profitability by Market Segments (Channel/Region)
22.5.5.3. Sales Footprint
22.5.5.4. Analyst commentary
22.5.5.5. Strategy Overview
22.5.5.5.1. Marketing Strategy
22.5.5.5.2. Product Strategy
22.5.5.5.3. Channel Strategy
22.5.6. Endo International plc. (Par Sterile Products, LLC)
22.5.6.1. Indication Portfolio
22.5.6.2. Profitability by Market Segments (Channel/Region)
22.5.6.3. Sales Footprint
22.5.6.4. Analyst commentary
22.5.6.5. Strategy Overview
22.5.6.5.1. Marketing Strategy
22.5.6.5.2. Product Strategy
22.5.6.5.3. Channel Strategy
22.5.7. Teva Pharmaceutical Industries Ltd.
22.5.7.1. Indication Portfolio
22.5.7.2. Profitability by Market Segments (Channel/Region)
22.5.7.3. Sales Footprint
22.5.7.4. Analyst commentary
22.5.7.5. Strategy Overview
22.5.7.5.1. Marketing Strategy
22.5.7.5.2. Product Strategy
22.5.7.5.3. Channel Strategy
22.5.8. Mylan N.V.
22.5.8.1. Indication Portfolio
22.5.8.2. Profitability by Market Segments (Channel/Region)
22.5.8.3. Sales Footprint
22.5.8.4. Analyst commentary
22.5.8.5. Strategy Overview
22.5.8.5.1. Marketing Strategy
22.5.8.5.2. Product Strategy
22.5.8.5.3. Channel Strategy
22.5.9. Wockhardt Ltd.
22.5.9.1. Indication Portfolio
22.5.9.2. Profitability by Market Segments (Channel/Region)
22.5.9.3. Sales Footprint
22.5.9.4. Analyst commentary
22.5.9.5. Strategy Overview
22.5.9.5.1. Marketing Strategy
22.5.9.5.2. Product Strategy
22.5.9.5.3. Channel Strategy
22.5.10. Sun Pharmaceutical Industries Ltd.
22.5.10.1. Indication Portfolio
22.5.10.2. Profitability by Market Segments (Channel/Region)
22.5.10.3. Sales Footprint
22.5.10.4. Analyst commentary
22.5.10.5. Strategy Overview
22.5.10.5.1. Marketing Strategy
22.5.10.5.2. Product Strategy
22.5.10.5.3. Channel Strategy
22.5.11. Yuhan Corporation
22.5.11.1. Indication Portfolio
22.5.11.2. Profitability by Market Segments (Channel/Region)
22.5.11.3. Sales Footprint
22.5.11.4. Analyst commentary
22.5.11.5. Strategy Overview
22.5.11.5.1. Marketing Strategy
22.5.11.5.2. Product Strategy
22.5.11.5.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Oxytocin Market
